RT Book, Section
A1 Thummel, Kenneth E.
A1 Shen, Danny D.
A1 Isoherranen, Nina
A2 Brunton, Laurence L.
A2 Chabner, Bruce A.
A2 Knollmann, Björn C.
SR Print(0)
ID 1127864485
T1 Design and Optimization of Dosage Regimens: Pharmacokinetic Data
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071624428
LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1127864485
RD 2022/05/18
AB This  appendix  provides  a  summary  of  basic  pharmacokinetic  information  pertaining  to  drugs  that  are  in  common  clinical  use  and  are  delivered  to  the  systemic  circulation  by  parenteral  or  non-parenteral  administration.  Because  of  space  limitations,  this  list  cannot  be  exhaustive.  Drugs  designed  exclusively  for  topical  administration  and  not  to  be  significantly  absorbed  into  the  bloodstream  (e.g.,  ophthalmic  and  some  dermal  applications;  Chapters  64  and  65)  are  not  included.  A  few  other  selection  criteria  have  influenced  the  makeup  of  the  list,  but,  in  general,  the  authors  have  tried  to  include  one  or  more  representative  drugs  in  each  of  the  therapeutic  areas  in  this  text,  based  on  distinct  mechanism(s)  of  action.  In  some  instances,  drugs  may  be  excluded  because  pharmacokinetics  are  not  relevant  to  their  therapeutic  management.  An  obvious  case  is  when  drug  efficacy  is  not  apparently  correlated  with  drug  concentration  in  a  reversible  fashion  (e.g.,  some  cytotoxic  anticancer  drugs).  Also,  for  a  number  of  therapeutic  antibodies,  the  antibody  is  administered  at  a  fixed  dose  at  prolonged  intervals  that  allows  for  its  near  complete  clearance  (e.g.,  infliximab).